Compare CTO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTO | OMER |
|---|---|---|
| Founded | 1902 | 1994 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 788.4M |
| IPO Year | N/A | 2008 |
| Metric | CTO | OMER |
|---|---|---|
| Price | $18.01 | $9.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $21.50 | ★ $32.50 |
| AVG Volume (30 Days) | 228.5K | ★ 697.9K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.07 | $2.95 |
| 52 Week High | $20.25 | $17.65 |
| Indicator | CTO | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 32.35 |
| Support Level | $17.14 | $9.31 |
| Resistance Level | $18.55 | $12.06 |
| Average True Range (ATR) | 0.34 | 0.49 |
| MACD | -0.15 | -0.13 |
| Stochastic Oscillator | 0.00 | 1.65 |
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.